Upcoming Events
Log In
Pricing
Free Trial

Wk 5, Case 1 - Review

HIDE
PrevNext

0:04

So the first case we have today is gonna be the modality,

0:08

thyroid, um, cancer patient.

0:10

Uh, these, uh, the thyroid cancer, as you guys know,

0:13

is a neuroendocrine tumor

0:15

or neuro um, so neuro um, endocrine cells.

0:18

So, um, dotatate is um, um, usually done.

0:23

You can, we can also do F DG PET as well.

0:26

Um, so I wanted to show you um, example

0:29

of a Dotatate PET CT done for thyroid cancer patient.

0:32

And this is, as you see here,

0:35

as I we did see in prior sessions,

0:38

you have to adjust the intensity.

0:39

This is the map. You have to adjust the intensity to be able

0:42

to see these cancers.

0:45

When I'm up here, again, I'm not gonna go

0:46

through my search pattern, I'm gonna directly go

0:49

to the findings.

0:51

When I'm the neck, I'll increase the intensity

0:53

to look at the thyroid first.

0:56

Look at this, it's enlarged.

0:58

Um, nitrogenous in the CT here.

1:02

Thyroid usually is hyper dense because the odine content.

1:06

But look how there is a large infiltrative ill-defined mass

1:10

replacing most of the thyroid gland.

1:13

And this mass in most part is intensely uh, dotatate Avid

1:18

or SSA avid heterogeneously, intensely avid.

1:21

And there's extension outside of the thyroid.

1:23

Obviously you can see here how it's extending

1:26

outside the thyroid gland infiltrating aju structures.

1:31

That traia you can,

1:32

you can't see like really assuming you guys to see, um,

1:36

there's no uh, flings with the trachea esophagus here.

1:41

Very large infiltrated mass in the thyroid gland, right?

1:45

Aggressive mass here.

1:47

And there's of course some necrosis here,

1:49

which is photonic in the pet damage, right?

1:52

And then when you go up here, it's always,

1:54

there's the static, uh, left cervical lymph nodes,

1:58

multiple metastatic left cervical lymph nodes,

2:00

obviously lymphatic SCA lymph nodes.

2:03

Right? Now of course you,

2:07

we will describe it in the report location, like

2:10

what are the levels of metastatic lymph nodes.

2:14

Um, and then, and be careful

2:17

because of course you know the parotid plant is the

2:19

physiologic side for the dotatate.

2:23

So don't confuse that with metastatic disease, right?

2:26

And um,

2:30

just like looking here in the mastoid here,

2:32

there is some activity in the mastoid.

2:33

Let me see here, what's going on.

2:46

This like something in the mastoid

2:47

or something in the rain.

2:51

Just took me a second. Dunno if we did notice that.

2:56

It's very subtle, very mild activity. Sometimes it's

2:59

Also the, the sinuses, the venous sinuses.

3:04

Let's see on the map,

3:10

see there's little, some ality here and I can go back

3:13

and look at the case and see if we saw something

3:16

and if the patient has correlative images

3:18

that showed something there.

3:20

In this here

3:27

there's a little bit widening.

3:29

Yeah, I don't think we recommended in that, right?

3:40

Yeah, I'll look at that and maybe follow up if you

3:43

send you a follow-up email.

3:49

Subtle like focal activity here, again,

3:52

you don't see it till you

3:53

really increase the intensity high.

3:55

If you look at the regular like intensity,

3:57

it's like it'll skip through and it, it might be nothing.

4:00

It's really the level of activity is um, blood pool level.

4:04

So it might be nothing, it's not metastatic or anything.

4:07

And if it's anything it's gonna be like maybe um, mening

4:10

or most probably a

4:13

mening if anything.

4:16

Or one of these like benign

4:20

lesions in the brain if something.

4:22

Or at most it's gonna be maybe inflammation.

4:26

I don't see evidence of mastitis right now

4:29

but I have to investigate it more.

4:35

I'll look at that and I will give you a follow up guys.

4:38

So let's go back to our case.

4:42

So there is here, like we said, primary thyroid,

4:45

me thyroid cancer with metastatic cervical lymph nodes.

4:49

And then um, when I go down

4:56

there was I think nothing in the lungs, not SS a avid

5:01

or even non um, S ss a avid

5:06

and you have to adjust the intensity when you go down here

5:09

into the liver to be able

5:10

to see like real any liver static lesions.

5:14

Lemme change the intensity here

5:19

and don't forget also to decrease the intensity

5:21

to look at the spleen nicely.

5:23

'cause when it's really very intense,

5:25

you can't see really anything in the spleen.

5:28

There's nothing in the spleen. The kidneys are fine.

5:31

Then we go back to the tendency to look forward

5:34

to the neo lymph nodes and there is nothing, right?

5:38

So looking at the MIP again, what

5:43

you can see is the medullary thyroid

5:47

can infiltrated, sorry,

5:49

the infiltrated moderate thyroid cancer

5:52

and metastatic lymph nodes that you can

5:56

See in this. So

5:57

regional lymph nodes and primary thyroid cancer.

6:01

Uh, that's all you can see in this patient.

6:03

And there was no, um, bone mets.

6:11

So keep in mind that modality,

6:12

thyroid cancer is a neuroendocrine in the

6:14

neuroendocrine tumor categories.

6:16

And um, dotatate is very valuable

6:19

and, um, helpful in this patient,

6:22

these patient population, right?

6:25

There's reactive inflammatory lymph

6:27

nodes in the inguinal region.

6:30

There's nothing here too. This is degenerative.

6:33

And as you know, um, we know that also what some, one

6:37

of the pitfalls of dotatate is that the same as a bg.

6:42

See here there's some activity, mild activity

6:45

because, um, osteoblastic,

6:49

so breast receptor receptors.

6:51

So when there's some active, uh, changes for example

6:55

or healing fractures, they will show some to the activity,

6:59

don't get confused

7:01

and think that there's something going on.

7:02

This is just when it's obviously degenerative changes,

7:05

it's ion, there's no problem with that.

7:07

And activity is usually mild, can be moderate,

7:10

not more than that, right?

7:12

So that is it for this patient. There's nothing extra.

Report

Please note: Items with dashed lines (--) are information withheld as it is not relevant for you to arrive at the correct findings and impression for the report and/or it was withheld for privacy information. The items were left in to show you the typical information documented in a PET report.

Clinical Indication:
----year-old male with T4bNab medullary thyroid cancer status post bronchoscopy with tracheal biopsy and tracheal balloon dilatation presenting for initial staging and treatment planning.

Technique:
Preparation: Not on Somatostatin Analogue Therapy.
Radiopharmaceutical: ------ mCi of Ga-68 dotatate (NETSPOT), a somatostatin analogue (SSA), administered intravenously at ------ at ---- PM
Incubation interval: ---- minutes.
Oral contrast: Not applicable.
Positioning: Arms by sides.
PET/CT scanner: Siemens Biograph 40 mCT.
PET/CT acquisition: Vertex-to-mid-thighs.
PET reconstruction method: Point Spread Function-Time of Flight (PSF-TOF), 2 iterations, 21 subsets, with and without CT-based attenuation correction.
Standardized uptake value (SUV): Corrected for body weight only.
CT: Low-dose, non-breath-hold, without intravenous contrast.
TOTAL DLP (Dose Length Product): ----- mGy cm.

Comparison/Correlation:
--

Findings:
Technical quality: Diagnostic.
Measurements: Unless otherwise specified, all SUVs refer to maximum value in the target (mSUV).

Reference: Mean SUV liver ---.

Head and Neck:
Heterogenous DOTA-avid infiltrative thyroid mass involving both thyroid lobes with encasement/involvement of the subglottic larynx, and upper trachea and associated moderately narrowing/stenosis, and extension inferiorly towards the superior mediastinum, and superiorly at the level of the thyroid cartilage, is compatible with biopsy proven primary medullary thyroid cancer, maximum SUV of 6.2, measures 56 x 49 mm.
Multiple intensely DOTA-avid left level IIB, III, IV and IVA lymph nodes, consistent with metastatic disease. Additional smaller left cervical lymph nodes with no significant activity are also seen. For reference purposes:

The dominant left level IIb/III lymph node demonstrates maximum SUV of 7.2, measures 15 mm in short axis.
Mild diffuse cerebral volume loss.
Paranasal sinuses and mastoid air cells are clear.


Chest:
No suspicious DOTA-avid foci in the chest.
Intrathoracic central airways are patent.
Calcified superior segment left lower lobe pulmonary granuloma.
No suspicious pulmonary nodule.
Mild cardiomegaly with dilated right and left ventricles.
Aorta is normal in caliber and course.
Main pulmonary artery is normal in caliber.


Abdomen and Pelvis:
No suspicious DOTA-avid foci in the abdomen or pelvis.
Physiologic activity in the spleen, adrenal glands, kidneys and the urinary bladder.
Unenhanced liver, gallbladder, adrenal glands, pancreas appear unremarkable.
Calcified splenic granulomata.
Nonobstructive left punctate nephrolithiasis.
Calcifications in the prostate gland.
No evidence of bowel obstruction.


Skeleton and Soft Tissues:
No suspicious DOTA-avid foci in the visualized osseous structures.
Reversal of the cervical spine lordosis centered at C3-4.
Advanced multilevel degenerative change in the spine, worse in the cervical and lumbar spine.

Impression:
1. Large DOTA-avid infiltrative thyroid mass with encasement/involvement of the larynx, and upper trachea with associated tracheal narrowing is compatible with biopsy proven medullary thyroid cancer.
2. Multiple DOTA-avid metastatic left cervical lymph nodes.
3. No evidence of DOTA-avid distant metastatic disease.

Case Discussion

Faculty

Riham El Khouli, MD

Associate Professor of Radiology, Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics

University of Kentucky

Michael F. Shriver, MD

Director of Nuclear Medicine

Proscan-NCH Imaging

Tags

Thyroid & Parathyroid

PET/CT DOTATATE

PET

Nuclear Medicine

CT